跳至主要内容
临床试验/EUCTR2012-004796-39-IT
EUCTR2012-004796-39-IT进行中(未招募)不适用

A Comparative Study of Oxycodone/Naloxone versus Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Knee and/or hip Pain Due to Osteoarthritis - PT-SM-14-OA

Fondazione IRCCS Policlinico San Matteo0 个研究点开始时间: 2013年4月23日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Male or female subjects older than 60 years old.
  • Subjects with a clinical diagnosis of degenerative or primary OA with moderate to severe chronic pain (NRS>4) that require around-the-clock opioid therapy. Subjects will identify the most painful joint (hip or knee) for documentation of OA. Pain measurement will be done at this joint only.
  • Subjects willing and able to participate in all aspects of the core study, including use of oral medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements as evidenced by providing written, informed consent.
  • Subjects in which the pre-study, non-opioid analgesics, and all other concomitant medications, including those medications for the treatment of depression are anticipated to remain stable throughout the treatment phase of the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 82
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 100

排除标准

  • Any history of hypersensitivity to oxycodone, naloxone, codeine, ibuprofen, or related products and ingredients.
  • Any contraindication to oxycodone, naloxone, codeine, paracetamol or ibuprofen.
  • Subjects with evidence of significant structural abnormalities of the GI tract (e.g., bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (e.g., ileus, hypothyroidism).
  • Subjects with cancer associated pain.
  • Subjects with secondary osteoarthritis (e.g. fracture, septic, acromegaly etc.).
  • Active alcohol or drug abuse and/or history of opioid abuse.
  • Subjects with Rheumatoid Arthritis.
  • Subjects with evidence of clinically unstable disease
  • Subjects with active or history of epilepsy
  • Subjects receiving hypnotics or other CNS depressants that, in the in Ivestigator's opinion, may pose a risk of additional CNS depression with opioid study medication
  • Subjects with evidence of impaired liver/kidney function upon entry into the study defined as: Aspartate aminotransferase, alanine aminotransferase (AST, ALT) levels >3 times the upper limit of normal; Gamma glutamyl transpeptidase (GGT) =5 times the upper limit of normal; Total bilirubin level outside of the reference range (unless the value is associated with pre documented Gilbert's Syndrome); cholinesterase <2000 UI; INR>2; Creatinine clearance < 40 ml/min.
  • Subjects with a history of depression or other psychiatric disorder that in the opinion of the investigator is significant enough to exclude the subject from the study.
  • Mental impaired patients.

研究者

相似试验